Back to results
US 9,051,294 B2Granted
Therapeutic agents
AssigneeAllergan, Inc.
InventorDavid W. Old
Life of this patent
Estimating the term…
Abstract
The invention provides well-defined compounds that are either EP2 agonists, EP4 agonists, or mixed EP2/EP4 agonist. The compounds are useful for treating a variety of pathological conditions associated with activity of the EP2 and/or EP4 receptors.
Claims11
A compound having the structure:
- wherein:
- Ar is aryl, heteroaryl, substituted aryl, or substituted heteroaryl, wherein substituents are selected from alkyl, alkenyl, alkynyl, hydroxyalkyl, hydroxyl, alkoxy, halogen, —CN, —CF3, —C(O)R1, —C(O)OR1, —C(O)CF3, —SO2N(R1)2, —SO2NH2, or —NO2;
- L is C1-C6 alkylene;
- A is arylene or heteroarylene;
- E is —CO2R1, —CH2OR1, —C(O)N(R1)2, or tetrazol-5-yl;
- each R1 is independently H, C1-C6 alkyl, phenyl, or biphenyl;
- and
- n is 0 or 1;
- or a pharmaceutically acceptable salt thereof.
6 more elements
A compound having the structure:
- or a pharmaceutically acceptable salt thereof.
Dependencies are inferred from the claim text.